| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate |
| 10 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On November 9, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s... |
| 06 Nov 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On November 4, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the l... |
| 30 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Chief Financial Officer and Principal Financial and Accounting Officer |
| 20 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Brisbane, CA, October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, ... |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
THIS MASTER SERVICE AGREEMENT (this “Agreement”) is entered into as of this 22 day of September 2026 (the “Effective Date”), by and between FACTOR BIOSCIENCE INC., a corporation organized and existing under the laws of the State of Delaw... |
| 17 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
THIS EXCLUSIVE COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of this 14th day of September 2026 (the “Effective Date”), by and between HEBEI SENLANG BIOTECHNOLOGY CO., LTD., a company organized and exi... |
| 16 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 15 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of September 11, 2026, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, inclu... |
| 24 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his positions as Principal Financial Officer and Principal Accounting Officer of the Company, and from any and ... |
| 18 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth q... |
| 13 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
PURCHASE AGREEMENT (the “Agreement”), dated as of August 13, 2026, by and between TEMPEST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investo... |
| 28 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 22 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This Product Development and Investigator-Initiated Trial (IIT) Collaboration Agreement (this “Agreement”) is entered into as of July 17, 2026 (the “Effective Date”) by and between: |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, the Company held its 2026 Special Meeting of Stockholder (the “Special Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Special Meeting are set forth below.... |
| 04 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Brisbane, CA, June 4, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the ... |
| 02 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
Loading...